OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Chaudhary on the Utilization of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer

September 29th 2023

Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.

Dr Desai on the Benefits and Limitations of Bladder Preservation With Chemoradiation in MIBC

September 28th 2023

Neil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.

Dr Nastoupil on the Background of the TRANSCEND FL Trial in Follicular Lymphoma

September 28th 2023

Loretta J. Nastoupil, MD, discusses the rationale for launching the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma, highlighting the background for investigating this treatment approach.

Dr Zhou on the Evaluation of Combination Therapies With Ruxolitinib in Myelofibrosis

September 28th 2023

Amy W. Zhou, MD, discusses the investigation of ruxolitinib given in conjunction with novel or emerging agents such as pacritinib and momelotinib, highlighting these agents’ potential at contributing to the treatment paradigm in myelofibrosis.

Dr Margulis on Patient Factors to Consider in the Treatment of RCC

September 28th 2023

Vitaly Margulis, MD, discusses significant factors and comorbidities that may affect treatment decisions for patients with renal cell carcinoma.

Dr Kurz on Social Determinants of Health That Contribute to Disparities in Cancer Care

September 28th 2023

Renee Kurz, DNP, FNP-BC, AOCNP, discusses social determinants of health that can contribute to disparities in cancer care, highlighting examples seen throughout New Jersey that emphasize the need for further investigation into this landscape.

Dr Bodor on a Study Profiling Estrogen Species in Women With EGFR-Mutated NSCLC

September 28th 2023

J. Nicholas Bodor, MD, PhD, MPH, discusses the results of prior research supporting the inception of a study that profiled reactive estrogen species in women with EGFR-positive non–small cell lung cancer, as well as the findings from this study.

Dr Aredo on the Molecular Distribution of Screening-Eligible Patients With NSCLC

September 28th 2023

Jacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.

Dr Beksac on OS Data From the OPTIMISMM Trial in Relapsed/Refractory Multiple Myeloma

September 28th 2023

Meral Beksac, MD, discusses overall survival data from the phase 3 OPTIMISMM trial in relapsed/refractory multiple myeloma.

Dr Talcott on Treatment De-Escalation in Elderly Patients With Breast Cancer

September 27th 2023

Wesley J. Talcott, MD, MBA, discusses the importance of de-escalating therapy in patients with breast cancer, highlighting use of personalized treatment approaches.

Dr Biachi on the Growing Treatment Landscape in HCC

September 27th 2023

Tiago Biachi, MD, PhD, discusses the growing treatment landscape for patients with hepatocellular carcinoma.

Dr Mastroyannis on the Administration and Utility of HIPEC in Ovarian Cancer

September 27th 2023

S. Alex Mastroyannis, MD, MSCE, discusses the administration and role of hyperthermic intraperitoneal chemotherapy in ovarian cancer, as well as its benefit for patients in the phase 3 OVHIPEC-1 trial.

Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate Cancer

September 27th 2023

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Dr Kulasinghe on a Study Profiling the NSCLC Tumor Microenvironment

September 27th 2023

Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.

Dr Billè on the Use of Minimally Invasive Surgery vs Stereotactic Radiotherapy in NSCLC

September 27th 2023

Andrea Billè, MD, discusses findings from a propensity-matched comparison of minimally invasive surgery vs stereotactic ablative radiotherapy in patients with clinical stage I non–small cell lung cancer.

Dr. Zhang on the Selection of Immunotherapy-Based Regimens in Metastatic RCC

September 27th 2023

Tian Zhang, MD, MHS, discusses the selection of first-line immunotherapy-based treatments for patients with metastatic renal cell carcinoma.

Dr Narayan on Variations in Breast Cancer Outcomes by Race

September 26th 2023

Anand Narayan, MD, PhD, discusses how outcomes differ between different subgroups of patients who are diagnosed with breast cancer, highlighting how these differences tie back to disparities in cancer care.

Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid Tumors

September 26th 2023

J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.

Dr Qin on the Use of CAR T-Cell Therapy in ccRCC

September 26th 2023

Qian (Janie) Qin, MD, discusses the investigation and use of CAR T-cell therapy in patients with advanced clear cell renal cell carcinoma.

Dr Margulis on Key Considerations When Navigating Frontline Combination Regimens in RCC

September 26th 2023

Vitaly Margulis, MD, discusses key disease characteristics and patient factors to consider when selecting between IO/IO vs IO/TKI treatment combinations for the management of patients with renal cell carcinoma.